Role of IL-33 and its receptor in T cell-mediated autoimmune diseases

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Zhao, Qing ^a   Chen, Guangjie ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 33; INTERLEUKIN 33 RECEPTOR; INTERLEUKIN RECEPTOR; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; IL1RL1 PROTEIN, HUMAN; IL33 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ANTIBODY SPECIFICITY; AUTOIMMUNE DISEASE; CELLULAR IMMUNITY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HOST RESISTANCE; HUMAN; IMMUNOREGULATION; INFLAMMATORY BOWEL DISEASE; MULTIPLE SCLEROSIS; NONHUMAN; PHYSIOLOGY; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; ANIMAL; IMMUNOLOGY; PATHOLOGY;

ANIMALS; AUTOIMMUNE DISEASES; HUMANS; IMMUNITY, CELLULAR; INTERLEUKINS; RECEPTORS, CELL SURFACE; T-LYMPHOCYTES;

EID: 84904124367     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/587376     Document Type: Review

References (101)

1. Onda H., Kasuya H., Takakura K., Hori T., Imaizumi T.-A., Takeuchi T., Inoue I., Takeda J., Identification of genes differentially expressed in canine vasospastic cerebral arteries after subarachnoid hemorrhage. Journal of Cerebral Blood Flow and Metabolism 1999 19 11 1279 1288 2-s2.0-0033510084 (Pubitemid 30176457)
2. Schmitz J., Owyang A., Oldham E., Song Y., Murphy E., McClanahan T. K., Zurawski G., Moshrefi M., Qin J., Li X., Gorman D. M., Bazan J. F., Kastelein R. A., IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005 23 5 479 490 2-s2.0-27744446058 10.1016/j.immuni.2005.09.015 (Pubitemid 41587888)
3. Cherry W. B., Yoon J., Bartemes K. R., Iijima K., Kita H., A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. Journal of Allergy and Clinical Immunology 2008 121 6 1484 1490 2-s2.0-44649129170 10.1016/j.jaci.2008.04.005 (Pubitemid 351787349)
4. Theoharides T. C., Alysandratos K.-D., Angelidou A., Delivanis D.-A., Sismanopoulos N., Zhang B., Asadi S., Vasiadi M., Weng Z., Miniati A., Kalogeromitros D., Mast cells and inflammation. Biochimica et Biophysica Acta-Molecular Basis of Disease 2012 1822 1 21 33 2-s2.0-82955220542 10.1016/j.bbadis.2010.12.014
5. Louten J., Rankin A. L., Li Y., Murphy E. E., Beaumont M., Moon C., Bourne P., Mcclanahan T. K., Pflanz S., de Waal Malefyt R., Endogenous IL-33 enhances Th2 cytokine production and T-cell responses during allergic airway inflammation. International Immunology 2011 23 5 307 315 2-s2.0-79955509396 10.1093/intimm/dxr006
6. Lettre G., Rioux J. D., Autoimmune diseases: insights from genome-wide association studies. Human Molecular Genetics 2008 17 2 R116 R121 2-s2.0-58149333555 10.1093/hmg/ddn246
7. Rosman Z., Shoenfeld Y., Zandman-Goddard G., Biologic therapy for autoimmune diseases: an update. BMC Medicine 2013 11 1, article 88 2-s2.0-84875687447 10.1186/1741-7015-11-88
8. Kakkar R., Hei H., Dobner S., Lee R. T., Interleukin 33 as a mechanically responsive cytokine secreted by living cells. Journal of Biological Chemistry 2012 287 9 6941 6948 2-s2.0-84857484469 10.1074/jbc.M111.298703
9. Seltmann J., Werfel T., Wittmann M., Evidence for a regulatory loop between IFN- γ and IL-33 in skin inflammation. Experimental Dermatology 2013 22 2 102 107 2-s2.0-84873191164 10.1111/exd.12076
10. Baekkevold E. S., Roussigné M., Yamanaka T., Johansen F.-E., Jahnsen F. L., Amalric F., Brandtzaeg P., Erard M., Haraldsen G., Girard J.-P., Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. American Journal of Pathology 2003 163 1 69 79 2-s2.0-0037631696 (Pubitemid 36759592)
11. Palmer G., Gabay C., Interleukin-33 biology with potential insights into human diseases. Nature Reviews Rheumatology 2011 7 6 321 329 2-s2.0-79958086613 10.1038/nrrheum.2011.53
12. Chapuis J., Hot D., Hansmannel F., Kerdraon O., Ferreira S., Hubans C., Maurage C. A., Huot L., Bensemain F., Laumet G., Ayral A. M., Fievet N., Hauw J. J., Dekosky S. T., Lemoine Y., Iwatsubo T., Wavrant-Devrièze F., Dartigues J. F., Tzourio C., Buée L., Pasquier F., Berr C., Mann D., Lendon C., Alpérovitch A., Kamboh M. I., Amouyel P., Lambert J. C., Transcriptomic and genetic studies identify IL-33 as a candidate gene for Alzheimer's disease. Molecular Psychiatry 2009 14 11 1004 1016 2-s2.0-70350568168 10.1038/mp.2009.10
13. Han P., Mi W.-L., Wang Y.-Q., Research progress on interleukin-33 and its roles in the central nervous system. Neuroscience Bulletin 2011 27 5 351 357 2-s2.0-81355135335 10.1007/s12264-011-1025-5
14. Cayrol C., Girard J.-P., The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proceedings of the National Academy of Sciences of the United States of America 2009 106 22 9021 9026 2-s2.0-67049158193 10.1073/pnas.0812690106
15. Lüthi A. U., Cullen S. P., McNeela E. A., Duriez P. J., Afonina I. S., Sheridan C., Brumatti G., Taylor R. C., Kersse K., Vandenabeele P., Lavelle E. C., Martin S. J., Suppression of Interleukin-33 Bioactivity through Proteolysis by Apoptotic Caspases. Immunity 2009 31 1 84 98 2-s2.0-68249137289 10.1016/j.immuni.2009.05.007
16. Sundlisæter E., Edelmann R. J., Hol J., Sponheim J., Kchler A. M., Weiss M., Udalova I. A., Midwood K. S., Kasprzycka M., Haraldsen G., The alarmin IL-33 is a notch target in quiescent endothelial cells. American Journal of Pathology 2012 181 3 1099 1111 2-s2.0-84865221699 10.1016/j.ajpath.2012.06.003
17. Ohno T., Oboki K., Kajiwara N., Morii E., Aozasa K., Flavell R. A., Okumura K., Saito H., Nakae S., Caspase-1, caspase-8, and calpain are dispensable for IL-33 release by macrophages. Journal of Immunology 2009 183 12 7890 7897 2-s2.0-76249084409 10.4049/jimmunol.0802449
18. Ali S., Nguyen D. Q., Falk W., Martin M. U., Caspase 3 inactivates biologically active full length interleukin-33 as a classical cytokine but does not prohibit nuclear translocation. Biochemical and Biophysical Research Communications 2010 391 3 1512 1516 2-s2.0-73949088791 10.1016/j.bbrc.2009.12. 107
19. Nakae S., Morita H., Ohno T., Arae K., Matsumoto K., Saito H., Role of Interleukin-33 in Innate-Type immune cells in allergy. Allergology International 2013 62 1 13 20 2-s2.0-84875160031 10.2332/allergolint.13-RAI-0538
20. Tominaga S., A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS Letters 1989 258 2 301 304 2-s2.0-0024404517 10.1016/0014- 5793(89)81679-5 (Pubitemid 20001074)
21. Luzina I. G., Pickering E. M., Kopach P., Kang P. H., Lockatell V., Todd N. W., Papadimitriou J. C., McKenzie A. N. J., Atamas S. P., Full-length IL-33 promotes inflammation but not Th2 response in vivo in an ST2-independent fashion. Journal of Immunology 2012 189 1 403 410 2-s2.0-84862838199 10.4049/jimmunol.1200259
22. Lin J., Zhang L., Zhao G., Su Z., Deng R., Pflugfelder S. C., Li D.-Q., A novel interleukin 33/ST2 signaling regulates inflammatory response in human corneal epithelium. PLoS ONE 2013 8 4 2-s2.0-84876069196 10.1371/journal.pone. 0060963 e60963
23. Oboki K., Ohno T., Kajiwara N., Saito H., Nakae S., IL-33 and IL-33 receptors in host defense and diseases. Allergology International 2010 59 2 143 160 2-s2.0-77954555721 10.2332/allergolint.10-RAI-0186
24. Smith D. E., IL-33: a tissue derived cytokine pathway involved in allergic inflammation and asthma. Clinical and Experimental Allergy 2010 40 2 200 208 2-s2.0-74049121313 10.1111/j.1365-2222.2009.03384.x
25. Ohno T., Morita H., Arae K., Matsumoto K., Nakae S., Interleukin-33 in allergy. Allergy 2012 67 10 1203 1214 2-s2.0-84866440902 10.1111/all.12004
26. Tominaga S., A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS Letters 1989 258 2 301 304 2-s2.0-0024404517 10.1016/0014- 5793(89)81679-5 (Pubitemid 20001074)
27. Mirchandani A. S., Salmond R. J., Liew F. Y., Interleukin-33 and the function of innate lymphoid cells. Trends in Immunology 2012 33 8 389 396 2-s2.0-84864145383 10.1016/j.it.2012.04.005
28. Ohno T., Oboki K., Kajiwara N., Morii E., Aozasa K., Flavell R. A., Okumura K., Saito H., Nakae S., Caspase-1, caspase-8, and calpain are dispensable for IL-33 release by macrophages. Journal of Immunology 2009 183 12 7890 7897 2-s2.0-76249084409 10.4049/jimmunol.0802449
29. Talabot-Ayer D., Calo N., Vigne S., Lamacchia C., Gabay C., Palmer G., The mouse interleukin (II)33 gene is expressed in a cell type- and stimulusdependent manner from two alternative promoters. Journal of Leukocyte Biology 2012 91 1 119 125 2-s2.0-84855315570 10.1189/jlb.0811425
30. Kondo Y., Yoshimoto T., Yasuda K., Futatsugi-yumikura S., Morimoto M., Hayashi N., Hoshino T., Fujimoto J., Nakanishi K., Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system. International Immunology 2008 20 6 791 800 2-s2.0-44849117539 10.1093/intimm/dxn037 (Pubitemid 351791523)
31. Kurowska-Stolarska M., Kewin P., Murphy G., Russo R. C., Stolarski B., Garcia C. C., Komai-Koma M., Pitman N., Li Y., McKenzie A. N. J., Teixeira M. M., Liew F. Y., Xu D., IL-33 induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4. Journal of Immunology 2008 181 7 4780 4790 2-s2.0-58149300244
32. Guo L. Y., Wei G., Zhu J. F., Liao W., Leonard W. J., Zhao K. J., Paul W., IL-1 family members and STAT activators induce cytokine production by Th2, Th17, and Th1 cells. Proceedings of the National Academy of Sciences of the United States of America 2009 106 32 13463 13468 2-s2.0-69449106110 10.1073/pnas.0906988106
33. Stampalija T., Chaiworapongsa T., Romero R., Tarca A. L., Bhatti G., Chiang P. J., Than N. G., Ferrazzi E., Hassan S. S., Yeo L., Soluble ST2, a modulator of the inflammatory response, in preterm and term labor. Journal of Maternal-Fetal and Neonatal Medicine 2014 27 2 111 121
34. Baba Y., Maeda K., Yashiro T., Inage E., Kasakura K., Suzuki R., Niyonsaba F., Hara M., Tanabe A., Ogawa H., Okumura K., Ohtsuka Y., Shimizu T., Nishiyama C., GATA2 is a critical transactivator for the human IL1RL1/ST2 promoter in mast cells/basophils: opposing roles for GATA2 and GATA1 in human IL1RL1/ST2 gene expression. Journal of Biological Chemistry 2012 287 39 32689 32696 2-s2.0-84866556250 10.1074/jbc.M112.374876
35. Hsu C.-L., Neilsen C. V., Bryce P. J., IL-33 is produced by mast cells and regulates IgE-dependent inflammation. PLoS ONE 2010 5 8 2-s2.0-77957787918 10.1371/journal.pone.0011944 e11944
36. Schneider E., Petit-Bertron A.-F., Bricard R., Levasseur M., Ramadan A., Girard J.-P., Herbelin A., Dy M., IL-33 activates unprimed murine basophils directly in vitro and induces their in vivo expansion indirectly by promoting hematopoietic growth factor production. Journal of Immunology 2009 183 6 3591 3597 2-s2.0-70349337464 10.4049/jimmunol.0900328
37. Smithgall M. D., Comeau M. R., Park Yoon B.-R., Kaufman D., Armitage R., Smith D. E., IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th 2 cells, iNKT and NK Cells. International Immunology 2008 20 8 1019 1030 2-s2.0-48449089903 10.1093/intimm/dxn060
38. Suzukawa M., Iikura M., Koketsu R., Nagase H., Tamura C., Komiya A., Nakae S., Matsushima K., Ohta K., Yamamoto K., Yamaguchi M., An IL-1 cytokine member, IL-33, induces human basophil activation via its ST2 receptor. Journal of Immunology 2008 181 9 5981 5989 2-s2.0-58149257537
39. Bonilla W. V., Fröhlich A., Senn K., Kallert S., Fernandez M., Johnson S., Kreutzfeldt M., Hegazy A. N., Schrick C., Fallon P. G., Klemenz R., Nakae S., Adler H., Merkler D., Löhning M., Pinschewer D. D., The alarmin interleukin-33 drives protective antiviral CD8+ T cell responses. Science 2012 335 6071 984 989 2-s2.0-84857640602 10.1126/science.1215418
40. Blom L., Poulsen B. C., Jensen B. M., Hansen A., Poulsen L. K., IL-33 induces IL-9 production in human CD4+ T cells and basophils. PLoS ONE 2011 6 7 2-s2.0-79959977906 10.1371/journal.pone.0021695 e21695
41. Milovanovic M., Volarevic V., Radosavljevic G., Jovanovic I., Pejnovic N., Arsenijevic N., Lukic M. L., IL-33/ST2 axis in inflammation and immunopathology. Immunologic Research 2012 52 1-2 89 99 2-s2.0-84859917147 10.1007/s12026-012-8283-9
42. Kim B. S., Siracusa M. C., Saenz S. A., Noti M., Monticelli L. A., Sonnenberg G. F., Hepworth M. R., van Voorhees A. S., Comeau M. R., Artis D., TSLP elicits IL-33-independent innate lymphoid cell responses to promote skin inflammation. Science Translational Medicine 2013 5 170 2-s2.0-84874055169 10.1126/scitranslmed.3005374 170ra16
43. Sattler S., Smits H. H., Xu D., Huang F.-P., The evolutionary role of the IL-33/ST2 system in host immune defence. Archivum Immunologiae et Therapiae Experimentalis 2013 61 2 107 117 2-s2.0-84879462169 10.1007/s00005-012-0208-8
44. Kurokawa M., Matsukura S., Kawaguchi M., Ieki K., Suzuki S., Watanabe S., Homma T., Yamaguchi M., Takeuchi H., Adachi M., Interleukin-33-activated dendritic cells induce the production of thymus and activation-regulated chemokine and macrophage-derived chemokine. International Archives of Allergy and Immunology 2013 161 supplement 2 52 57 2-s2.0-84880522421 10.1159/000350363
45. Su Z., Lin J., Lu F., Zhang X., Zhang L., Gandhi N. B., De Paiva C. S., Pflugfelder S. C., Li D.-Q., Potential autocrine regulation of interleukin-33/ST2 signaling of dendritic cells in allergic inflammation. Mucosal Immunology 2013 6 5 921 930 2-s2.0-84883187953 10.1038/mi.2012.130
46. Palmer G., Talabot-Ayer D., Lamacchia C., Toy D., Seemayer C. A., Viatte S., Finckh A., Smith D. E., Gabay C., Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis and Rheumatism 2009 60 3 738 749 2-s2.0-61649117392 10.1002/art.24305
47. Oboki K., Nakae S., Matsumoto K., Saito H., IL-33 and airway inflammation. Allergy, Asthma and Immunology Research 2011 3 2 81 88 2-s2.0-79953193447 10.4168/aair.2011.3.2.81
48. Kakkar R., Lee R. T., The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nature Reviews Drug Discovery 2008 7 10 827 840 2-s2.0-53249113212 10.1038/nrd2660
49. Haraldsen G., Balogh J., Pollheimer J., Sponheim J., Küchler A. M., Interleukin-33-cytokine of dual function or novel alarmin? Trends in Immunology 2009 30 5 227 233 2-s2.0-65149097030 10.1016/j.it.2009.03.003
50. Chackerian A. A., Oldham E. R., Murphy E. E., Schmitz J., Pflanz S., Kastelein R. A., IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. Journal of Immunology 2007 179 4 2551 2555 2-s2.0-34848899012
51. Palmer G., Lipsky B. P., Smithgall M. D., Meininger D., Siu S., Talabot-Ayer D., Gabay C., Smith D. E., The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33. Cytokine 2008 42 3 358 364 2-s2.0-44449104907 10.1016/j.cyto.2008.03.008
52. Hong J., Bae S., Jhun H., Lee S., Choi J., Kang T., Kwak A., Hong K., Kim E., Jo S., Kim S., Identification of constitutively active interleukin 33 (IL-33) splice variant. Journal of Biological Chemistry 2011 286 22 20078 20086 2-s2.0-79957595391 10.1074/jbc.M111.219089
53. Mu R., Huang H.-Q., Li Y.-H., Li C., Ye H., Li Z.-G., Elevated serum interleukin 33 is associated with autoantibody production in patients with rheumatoid arthritis. Journal of Rheumatology 2010 37 10 2006 2013 2-s2.0-77957883154 10.3899/jrheum.100184
54. Matsuyama Y., Okazaki H., Tamemoto H., Kimura H., Kamata Y., Nagatani K., Nagashima T., Hayakawa M., Iwamoto M., Yoshio T., Tominaga S.-I., Minota S., Increased levels of interleukin 33 in sera and synovial fluid from patients with active rheumatoid arthritis. Journal of Rheumatology 2010 37 1 18 25 2-s2.0-73649098450 10.3899/jrheum.090492
55. Martin P., Talabot-Ayer D., Seemayer C. A., Vigne S., Lamacchia C., Rodriguez E., Finckh A., Smith D. E., Gabay C., Palmer G., Disease severity in K/BxN serum transfer-induced arthritis is not affected by IL-33 deficiency. Arthritis Research and Therapy 2013 15 1, article R13 2-s2.0-84872187641 10.1186/ar4143
56. Scarisbrick I. A., Linbo R., Vandell A. G., Keegan M., Blaber S. I., Blaber M., Sneve D., Lucchinetti C. F., Rodriguez M., Diamandis E. P., Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration. Biological Chemistry 2008 389 6 739 745 2-s2.0-47549115421 10.1515/BC.2008.085 (Pubitemid 352009418)
57. Karpus W. J., Kennedy K. J., Fife B. T., Bennett J. L., Dal Canto M. C., Kunkel S. L., Lukacs N. W., Anti-CCL2 treatment inhibits Theiler's murine encephalomyelitis virus-induced demyelinating disease. Journal of NeuroVirology 2006 12 4 251 261 2-s2.0-33748656556 10.1080/13550280600873819 (Pubitemid 44382977)
58. Christophi G. P., Gruber R. C., Panos M., Christophi R. L., Jubelt B., Massa P. T., Interleukin-33 upregulation in peripheral leukocytes and CNS of multiple sclerosis patients. Clinical Immunology 2012 142 3 308 319 2-s2.0-84857370530 10.1016/j.clim.2011.11.007
59. Ali S., Mohs A., Thomas M., Klare J., Ross R., Schmitz M. L., Martin M. U., The dual function cytokine IL-33 interacts with the transcription factor NF- B to dampen NF- B-stimulated gene transcription. Journal of Immunology 2011 187 4 1609 1616 2-s2.0-80051926552 10.4049/jimmunol.1003080
60. Hudson C. A., Christophi G. P., Gruber R. C., Wilmore J. R., Lawrence D. A., Massa P. T., Induction of IL-33 expression and activity in central nervous system glia (Journal of Leukocyte Biology (2008), 84). Journal of Leukocyte Biology 2011 89 2 319 2-s2.0-79951820549 10.1189/jlb.1207830err
61. Li M., Li Y., Liu X., Gao X., Wang Y., IL-33 blockade suppresses the development of experimental autoimmune encephalomyelitis in C57BL/6 mice. Journal of Neuroimmunology 2012 247 1-2 25 31 2-s2.0-84860838601 10.1016/j.jneuroim.2012.03.016
62. Jiang H.-R., Milovanović M., Allan D., Niedbala W., Besnard A.-G., Fukada S. Y., Alves-Filho J. C., Togbe D., Goodyear C. S., Linington C., Xu D., Lukic M. L., Liew F. Y., IL-33 attenuates EAE by suppressing IL-17 and IFN- γ production and inducing alternatively activated macrophages. European Journal of Immunology 2012 42 7 1804 1814 2-s2.0-84864002777 10.1002/eji.201141947
63. Milovanovic M., Volarevic V., Ljujic B., Radosavljevic G., Jovanovic I., Arsenijevic N., Lukic M. L., Deletion of IL-33R (ST2) abrogates resistance to EAE in BALB/C mice by enhancing polarization of APC to inflammatory phenotype. PLoS ONE 2012 7 9 2-s2.0-84866478819 10.1371/journal.pone.0045225 e45225
64. Mangini A. J., Lafyatis R., van Seventer J. M., Shoenfeld Y., Gershwin M. E., Type I interferons inhibition of inflammatory T helper cell responses in systemic lupus erythematosus. Autoimmunity, Partt D: Autoimmune Disease, Annus Mirabilis 2007 11 23 (Pubitemid 47528714)
65. Kuroiwa K., Arai T., Okazaki H., Minota S., Tominaga S.-I., Identification of human ST2 protein in the sera of patients with autoimmune diseases. Biochemical and Biophysical Research Communications 2001 284 5 1104 1108 2-s2.0-0034816240 10.1006/bbrc.2001.5090 (Pubitemid 32917952)
66. Mok M. Y., Huang F. P., Ip W. K., Lo Y., Wong F. Y., Chan E. Y. T., Lam K. F., Xu D., Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus. Rheumatology 2009 49 3 520 527 2-s2.0-77950534152 10.1093/rheumatology/kep402
67. Beltrán C. J., Núñez L. E., Díaz- Jiménez D., Farfan N., Candia E., Heine C., López F., González M. J., Quera R., Hermoso M. A., Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease. Inflammatory Bowel Diseases 2010 16 7 1097 1107 2-s2.0-77953721901 10.1002/ibd.21175
68. Kobori A., Yagi Y., Imaeda H., Ban H., Bamba S., Tsujikawa T., Saito Y., Fujiyama Y., Andoh A., Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis. Journal of Gastroenterology 2010 45 10 999 1007 2-s2.0-78249249625 10.1007/s00535-010-0245-1
69. Pastorelli L., Garg R. R., Hoang S. B., Spina L., Mattioli B., Scarpa M., Fiocchi C., Vecchi M., Pizarro T. T., Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proceedings of the National Academy of Sciences of the United States of America 2010 107 17 8017 8022 2-s2.0-77952324145 10.1073/pnas.0912678107
70. Seidelin J. B., Bjerrum J. T., Coskun M., Widjaya B., Vainer B., Nielsen O. H., IL-33 is upregulated in colonocytes of ulcerative colitis. Immunology Letters 2010 128 1 80 85 2-s2.0-74649085973 10.1016/j.imlet.2009.11.001
71. Bamias G., Martin C. III, Mishina M., Ross W. G., Rivera-Nieves J., Marini M., Cominelli F., Proinflammatory effects of TH2 cytokines in a murine model of chronic small intestinal inflammation. Gastroenterology 2005 128 3 654 666 2-s2.0-15744391229 10.1053/j.gastro.2004.11.053 (Pubitemid 40585368)
72. Garlanda C., Anders H.-J., Mantovani A., TIR8/SIGIRR: an IL-1R/TLR family member with regulatory functions in inflammation and T cell polarization. Trends in Immunology 2009 30 9 439 446 2-s2.0-68949181883 10.1016/j.it.2009.06. 001
73. Hammad H., Chieppa M., Perros F., Willart M. A., Germain R. N., Lambrecht B. N., House dust mite allergen induces asthma via Toll-like receptor 4 triggering of airway structural cells. Nature Medicine 2009 15 4 410 416 2-s2.0-64149087970 10.1038/nm.1946
74. Bulek K., Swaidani S., Qin J. Z., Lu Y., Gulen M. F., Herjan T., Min B., Kastelein R. A., Aronica M., Kosz-Vnenchak M., Li X., The essential role of single Ig IL-1 receptor-related molecule/Toll IL-1R8 in regulation of Th2 immune response. Journal of Immunology 2009 182 5 2601 2609 2-s2.0-64849087206 10.4049/jimmunol.0802729
75. Garlanda C., Riva F., Polentarutti N., Buracchi C., Sironi M., De Bortoli M., Muzio M., Bergottini R., Scanziani E., Vecchi A., Hirsch E., Mantovani A., Intestinal inflammation in mice deficient in Tir8, an inhibitory member of the IL-1 receptor family. Proceedings of the National Academy of Sciences of the United States of America 2004 101 10 3522 3526 2-s2.0-12144287484 10.1073/pnas.0308680101 (Pubitemid 38338228)
76. Milovanovic M., Volarevic V., Radosavljevic G., Jovanovic I., Pejnovic N., Arsenijevic N., Lukic M. L., IL-33/ST2 axis in inflammation and immunopathology. Immunologic Research 2012 52 1-2 89 99 2-s2.0-84859917147 10.1007/s12026-012-8283-9
77. Kageyama Y., Torikai E., Tsujimura K., Kobayashi M., Involvement of IL-33 in the pathogenesis of rheumatoid arthritis: the effect of etanercept on the serum levels of IL-33. Modern Rheumatology 2012 22 1 89 93 2-s2.0-84861483082 10.1007/s10165-011-0480-1
78. Barksby H. E., Lea S. R., Preshaw P. M., Taylor J. J., The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders. Clinical and Experimental Immunology 2007 149 2 217 225 2-s2.0-34447324371 10.1111/j.1365-2249.2007.03441.x (Pubitemid 47063063)
79. Leung B. P., Xu D., Culshaw S., McInnes I. B., Liew F. Y., A novel therapy of murine collagen-induced arthritis with soluble T1/ST2. Journal of Immunology 2004 173 1 145 150 2-s2.0-2942702125 (Pubitemid 38797335)
80. Lingel A., Weiss T. M., Niebuhr M., Pan B., Appleton B. A., Wiesmann C., Bazan J. F., Fairbrother W. J., Structure of IL-33 and its interaction with the ST2 and IL-1RAcP receptors-insight into heterotrimeric IL-1 signaling complexes. Structure 2009 17 10 1398 1410 2-s2.0-70349759672 10.1016/j.str.2009.08.009
81. Sanada S., Hakuno D., Higgins L. J., Schreiter E. R., McKenzie A. N. J., Lee R. T., IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. Journal of Clinical Investigation 2007 117 6 1538 1549 2-s2.0-34249882513 10.1172/JCI30634 (Pubitemid 46871338)
82. Xu D., Jiang H.-R., Kewin P., Li Y., Mu R., Fraser A. R., Pitman N., Kurowska-Stolarska M., McKenzie A. N. J., McInnes I. B., Liew F. Y., IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proceedings of the National Academy of Sciences of the United States of America 2008 105 31 10913 10918 2-s2.0-49449111630 10.1073/pnas.0801898105
83. Talabot-Ayer D., McKee T., Gindre P., Bas S., Baeten D. L., Gabay C., Palmer G., Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Joint Bone Spine 2012 79 1 32 37 2-s2.0-84855653658 10.1016/j.jbspin.2011.02.011
84. Verri W. A. Jr., Souto F. O., Vieira S. M., Almeida S. C. L., Fukada S. Y., Xu D., Alves-Filho J. C., Cunha T. M., Guerrero A. T. G., Mattos-Guimaraes R. B., Oliveira F. R., Teixeira M. M., Silva J. S., McInnes I. B., Ferreira S. H., Louzada P. Jr., Liew F. Y., Cunha F. Q., IL-33 induces neutrophil migration in rheumatoid arthritis and is a target of anti-TNF therapy. Annals of the Rheumatic Diseases 2010 69 9 1697 1703 2-s2.0-77956024623 10.1136/ard.2009. 122655
85. Miller A. M., Xu D., Asquith D. L., Denby L., Li Y., Sattar N., Baker A. H., McInnes I. B., Liew F. Y., IL-33 reduces the development of atherosclerosis. Journal of Experimental Medicine 2008 205 2 339 346 2-s2.0-39549100797 10.1084/jem.20071868 (Pubitemid 351281600)
86. Andre R., Lerouet D., Kimber I., Pinteaux E., Rothwell N. J., Regulation of expression of the novel IL-1 receptor family members in the mouse brain. Journal of Neurochemistry 2005 95 2 324 330 2-s2.0-26844554608 10.1111/j.1471-4159.2005.03364.x (Pubitemid 41457501)
87. Yasuoka S., Kawanokuchi J., Parajuli B., Jin S., Doi Y., Noda M., Sonobe Y., Takeuchi H., Mizuno T., Suzumura A., Production and functions of IL-33 in the central nervous system. Brain Research 2011 1385 8 17 2-s2.0-79953176269 10.1016/j.brainres.2011.02.045
88. Hudson C. A., Christophi G. P., Gruber R. C., Wilmore J. R., Lawrence D. A., Massa P. T., Induction of IL-33 expression and activity in central nervous system glia. Journal of Leukocyte Biology 2008 84 3 631 643 2-s2.0-50849142256 10.1189/jlb.1207830
89. Kornek B., Lassmann H., Neuropathology of multiple sclerosis-new concepts. Brain Research Bulletin 2003 61 3 321 326 2-s2.0-0041589180 10.1016/S0361-9230(03)00095-9 (Pubitemid 36952478)
90. Christophi G. P., Hudson C. A., Panos M., Gruber R. C., Massa P. T., Modulation of macrophage infiltration and inflammatory activity by the phosphatase SHP-1 in virus-induced demyelinating disease. Journal of Virology 2009 83 2 522 539 2-s2.0-58149502606 10.1128/JVI.01210-08
91. Zhang L., Lu R., Zhao G., Pflugfelder S. C., Li D.-Q., TLR-mediated induction of pro-allergic cytokine IL-33 in ocular mucosal epithelium. International Journal of Biochemistry and Cell Biology 2011 43 9 1383 1391 2-s2.0-79960924748 10.1016/j.biocel.2011.06.003
92. Lamkanfi M., Dixit V. M., Modulation of inflammasome pathways by bacterial and viral pathogens. Journal of Immunology 2011 187 2 596 602 2-s2.0-79960502623 10.4049/jimmunol.1100229
93. Yang Z., Liang Y., Xi W., Li C., Zhong R., Association of increased serum IL-33 levels with clinical and laboratory characteristics of systemic lupus erythematosus in Chinese population. Clinical and Experimental Medicine 2011 11 2 75 80 2-s2.0-79958142088 10.1007/s10238-010-0115-4
94. Lech M., Kulkarni O. P., Pfeiffer S., Savarese E., Krug A., Garlanda C., Mantovani A., Anders H.-J., Tir8/Sigirr prevents murine lupus by suppressing the immunostimulatory effects of lupus autoantigens. Journal of Experimental Medicine 2008 205 8 1879 1888 2-s2.0-49249109576 10.1084/jem.20072646
95. Díaz-Jiménez D., Núñez L. E., Beltrán C. J., Candia E., Suazo C., Álvarez-Lobos M., González M.-J., Hermoso M. A., Quera R., Soluble ST2: a new and promising activity marker in ulcerative colitis. World Journal of Gastroenterology 2011 17 17 2181 2190 2-s2.0-79955857793 10.3748/wjg.v17.i17.2181
96. Pastorelli L., de Salvo C., Vecchi M., GvPizarro T. T., The role of IL-33 in gut mucosal inflammation. Mediators of Inflammation 2013 2013 11 2-s2.0-84878636647 10.1155/2013/608187 608187
97. Sedhom M. A. K., Pichery M., Murdoch J. R., Foligné B., Ortega N., Normand S., Mertz K., Sanmugalingam D., Brault L., Grandjean T., Lefrancais E., Fallon P. G., Quesniaux V., Peyrin-Biroulet L., Cathomas G., Junt T., Chamaillard M., Girard J.-P., Ryffel B., Neutralisation of the interleukin-33/ST2 pathway ameliorates experimental colitis through enhancement of mucosal healing in mice. Gut 2013 62 1714 1723 2-s2.0-84869212351 10.1136/gutjnl-2011-301785
98. Groß P., Doser K., Falk W., Obermeier F., Hofmann C., IL-33 attenuates development and perpetuation of chronic intestinal inflammation. Inflammatory Bowel Diseases 2012 18 10 1900 1909 2-s2.0-84866386408 10.1002/ibd.22900
99. Pushparaj P. N., Li D., Komai-Koma M., Guabiraba R., Alexander J., Mcsharry C., Xu D., Interleukin-33 exacerbates acute colitis via interleukin-4 in mice. Immunology 2013 140 1 70 77 2-s2.0-84878642267 10.1111/imm.12111
100. Latiano A., Palmieri O., Pastorelli L., Vecchi M., Pizarro T. T., Bossa F., Merla G., Augello B., Latiano T., Corritore G., Settesoldi A., Valvano M. R., D'Incà R., Stronati L., Annese V., Andriulli A., Associations between genetic polymorphisms in IL-33, IL1R1 and risk for inflammatory bowel disease. PLoS ONE 2013 8 4 2-s2.0-84876740406 10.1371/journal.pone.0062144 e62144
101. Murphy G. E. J., Xu D., Liew F. Y., McInnes I. B., Role of interleukin 33 in human immunopathology. Annals of the Rheumatic Diseases 2010 69 1 i43 i47 2-s2.0-75749087164 10.1136/ard.2009.120113